Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
63.83 USD | -0.65% |
|
+4.75% | +1.26% |
01:06pm | JPMorgan Adjusts Price Target on Incyte to $59 From $60, Maintains Neutral Rating | MT |
12:55pm | Goldman Sachs Adjusts Price Target on Incyte to $61 From $60, Maintains Neutral Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.26% | 14.45B | |
+7.40% | 101B | |
+8.42% | 42.18B | |
-13.44% | 32.26B | |
+80.80% | 29.79B | |
-11.74% | 16.06B | |
-6.77% | 12.01B | |
+177.16% | 10.71B | |
+4.12% | 8.89B | |
-56.13% | 8.83B |
- Stock Market
- Equities
- INCY Stock
- News Incyte Corporation
- Transcript : Calithera Biosciences, Inc., Incyte Corporation - Special Call